Bregolis

Bregolis is a synthetic opioid analgesic developed by the pharmaceutical company Reckitt Benckiser. It is a prodrug, meaning it is inactive until metabolized in the body, and it is structurally related to morphine. Bregolis is designed to be a long-acting opioid, with a duration of action of up to 72 hours. It is indicated for the management of moderate to severe pain, including cancer pain, postoperative pain, and chronic pain.

The active metabolite of Bregolis is norbregoline, which is a mu-opioid receptor agonist. It acts on the same receptors as morphine, but with a different pharmacokinetic profile. Bregolis is administered orally, and it is available in tablet form. The most common side effects of Bregolis include constipation, nausea, and dizziness. Serious side effects can include respiratory depression, seizures, and allergic reactions.

Bregolis is approved for medical use in several countries, including the United Kingdom, Canada, and Australia. However, its use is controversial due to concerns about its potential for abuse and dependence. It is classified as a Schedule II drug in the United States, indicating that it has a high potential for abuse and dependence, but it is not approved for use in the U.S. market.

The development of Bregolis was halted in the United States in 2010 due to concerns about its potential for abuse. However, it continues to be marketed and prescribed in other countries. The World Health Organization has expressed concerns about the potential for misuse of Bregolis and has called for more research into its safety and efficacy. As of now, Bregolis remains a topic of debate in the medical community, with ongoing discussions about its appropriate use and potential risks.